JP2018177702A - Skin aging inhibitor containing hydrangea paniculata siebold extract as active ingredient and skin external preparation containing the same - Google Patents
Skin aging inhibitor containing hydrangea paniculata siebold extract as active ingredient and skin external preparation containing the same Download PDFInfo
- Publication number
- JP2018177702A JP2018177702A JP2017080347A JP2017080347A JP2018177702A JP 2018177702 A JP2018177702 A JP 2018177702A JP 2017080347 A JP2017080347 A JP 2017080347A JP 2017080347 A JP2017080347 A JP 2017080347A JP 2018177702 A JP2018177702 A JP 2018177702A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- external preparation
- siebold
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000004480 active ingredient Substances 0.000 title claims abstract description 6
- 241000511974 Hydrangea paniculata Species 0.000 title claims abstract description 5
- 230000009759 skin aging Effects 0.000 title abstract description 7
- 239000003112 inhibitor Substances 0.000 title abstract 6
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 230000003712 anti-aging effect Effects 0.000 claims description 13
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000004983 pleiotropic effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 210000003491 skin Anatomy 0.000 description 23
- 239000002537 cosmetic Substances 0.000 description 18
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229940015043 glyoxal Drugs 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000036252 glycation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 244000267823 Hydrangea macrophylla Species 0.000 description 2
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241000209490 Nymphaea Species 0.000 description 2
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 description 2
- 244000018795 Prunus mume Species 0.000 description 2
- 235000011158 Prunus mume Nutrition 0.000 description 2
- 244000086363 Pterocarpus indicus Species 0.000 description 2
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- -1 coumarin glucoside Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001092080 Hydrangea Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229930182491 iridoid glucoside Natural products 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、皮膚老化防止剤、特に、ノリウツギ(Hydrangea paniculata siebold)抽出物を有効成分として含有するものであって、その有効性が、抗炎症機能、抗糖化機能向上に基づくものに関し、さらに当該皮膚老化防止剤を配合した皮膚外用剤に関する。 The present invention relates to a skin anti-aging agent, in particular, an extract containing Hydrangea paniculata siebold as an active ingredient, the efficacy of which is based on the improvement of anti-inflammatory function and anti-glycation function, The present invention relates to a skin external preparation containing a skin anti-aging agent.
皮膚は生体の最外層に位置することから、環境からのストレスに絶えず曝される器官である。環境ストレスの中でも乾燥や紫外線などは皮膚の炎症を引き起こすことが知られている。また、皮膚バリア機能が低下した状態では、外来物質の侵入による炎症が引き起こされやすい状態となる。皮膚炎症は皮膚疾患又は皮膚癌の原因となるだけではなく、肌荒れの原因ともなる。 Since the skin is located on the outermost layer of the living body, it is an organ that is constantly exposed to environmental stress. Among environmental stress, dryness and ultraviolet rays are known to cause skin inflammation. In addition, when the skin barrier function is reduced, inflammation due to the entry of foreign substances is likely to be caused. Skin inflammation not only causes skin diseases or skin cancer, but also causes rough skin.
紫外線や微生物などの炎症誘発因子の刺激を受けた表皮角化細胞では、種々のシグナル伝達経路が活性化され、転写因子の一つであるNuclear factor - kappa B (NF-κB) が活性化される。活性化したNF-κBはInterleukinやtumor necrosis factor-alphaなどの炎症性サイトカインの遺伝子発現を誘導することで炎症反応を惹起する。NF-κBの活性化や炎症性サイトカインの発現を抑制することは、炎症反応を抑制する上で有効な手段と考えられている。 In epidermal keratinocytes stimulated with UV and inflammation-inducing factors such as microorganisms, various signal transduction pathways are activated and nuclear factor-kappa B (NF-κB), one of the transcription factors, is activated. Ru. Activated NF-κB induces an inflammatory response by inducing gene expression of inflammatory cytokines such as Interleukin and tumor necrosis factor-alpha. It is considered that suppressing the activation of NF-κB and the expression of inflammatory cytokines is an effective means for suppressing the inflammatory response.
還元糖とタンパク質との反応に始まる糖化反応(メイラード反応)は食品中の反応として発見されたが、その後、生体内でも起こる反応であることが明らかになった。糖化反応は大別するとアマドリ転移物が生成するまでの前期反応とその後、酸化・脱水・縮合を経て最終糖化産物であるAdvanced Glycation End products(AGEs)が生成される後期反応に分けられる。AGEsにより修飾されたタンパク質は、構造的あるいはそれに伴う機能的な変化を引き起こし、生体に悪影響を及ぼす。また、AGEsがAGEs受容体であるRAGEに結合することにより炎症シグナルが惹起されることも知られている。皮膚においてもAGEsの存在が認められており、皮膚の弾力低下、黄色化の一因とされている。これらのことから、AGEsの蓄積を阻害することは皮膚老化予防において重要であるといえる。AGEsの蓄積を阻害するアプローチとしては、(1)AGEsの生成を阻害する、(2)生成されたAGEsを分解することが挙げられる。 The saccharification reaction (Maillard reaction) that starts with the reaction between reducing sugars and proteins was discovered as a reaction in food, but was later revealed to be a reaction that also occurs in vivo. The glycation reaction is roughly divided into a pre-reaction until the formation of an Amadori transferred product and a post-reaction which is followed by oxidation, dehydration and condensation to produce Advanced Glycation End products (AGEs) which are final glycation products. Proteins modified by AGEs cause structural changes or functional changes associated therewith, which adversely affect living organisms. In addition, it is also known that inflammatory signals are triggered by binding of AGEs to RAGE which is an AGEs receptor. The presence of AGEs is also found in the skin, and is considered to be a cause of the skin's reduced elasticity and yellowing. From these facts, it can be said that inhibiting the accumulation of AGEs is important in preventing skin aging. Approaches to inhibit the accumulation of AGEs include (1) inhibiting the formation of AGEs and (2) degrading the generated AGEs.
ノリウツギは、ユキノシタ科アジサイ属の落葉低木であり、昆虫の目を引く装飾花と受粉を行う両性花からなる円錐形の花序をつける。ノリウツギ(糊空木)と言う名の通り、樹皮には多量の粘液を含むため、和紙を漉くときの糊料として戦前から利用され、また、現在でも 繊維を均一に分散するために使われている。ノリウツギの幹の内部は中空であるため、パイプとしての利用もある。他のアジサイ種が山中の半日陰地を好むのに対し、本種は林縁部だけでなく、陽のよく当たる原野及び湿原にも自生しており、日本全域で見ることができる。 Nori-utsugi is a deciduous shrub of the family Anchovyaceae Hydrangea and has a conical inflorescence consisting of decorative flowers that attracts insects and bisexual flowers that pollinate. As the name says Noriutsugi (glued sky wood), the bark contains a large amount of mucus, so it is used before the war as a paste for making Japanese paper, and it is still used to disperse fibers evenly. There is. Since the inside of the stem of the apricot tree is hollow, it can be used as a pipe. While other hydrangea species prefer semi-shaded areas in the mountains, this species is not only found on forest edges, but also on wild sunny and sunny fields and can be found throughout Japan.
特許文献1には、メラニン生成抑制作用に優れ、シミやソバカスの改善効果に優れた美白化粧料として、ノリウツギを含む群の植物エキスまたはそのアルカリ処理物を一種または二種以上配合する技術が記載されている。 Patent Document 1 describes a technology for blending one or two or more kinds of plant extracts of a group including Nori-utsuji or alkali-treated products thereof as a whitening cosmetic which is excellent in melanin production suppressive action and excellent in improving stains and buckwheat. It is done.
特許文献2には、ユキノシタ科の植物の抽出物が美白効果を有すること、そして、該植物としてアジサイが記載されている。 Patent Document 2 describes that an extract of a plant of the family Citrusaceae has a whitening effect, and hydrangea is described as the plant.
非特許文献1には、ノリウツギから特定条件で抽出された赤色色素の物性が開示されており、炭水化物の保護作用を有することが報告されている。 Non-Patent Document 1 discloses the physical properties of a red pigment extracted from Noriutsugi under specific conditions, and is reported to have a carbohydrate protecting action.
非特許文献2には、ノリウツギの樹皮から抽出した粘液性組成物からポリサッカライドを単離したこと、そしてその物性について報告されている。 Non-Patent Document 2 reports that the polysaccharide was isolated from a mucous composition extracted from the bark of Noriutsugi and its physical properties.
非特許文献3には、ノリウツギ由来のクマリン配糖体とイリドイド配糖体が神経保護作用を有する旨が報告されている。 Non-Patent Document 3 reports that the coumarin glucoside derived from Noriutsugi and the iridoid glucoside have a neuroprotective action.
しかし、これらのいずれにも、ノリウツギ抽出物の抗炎症機能、抗糖化機能、保湿機能の向上や、これらの有効性に基づいた皮膚老化防止剤への応用についての記載や示唆は存在しない。 However, none of these describes or suggests the anti-inflammatory function, the anti-glycation function, the moisturizing function of Nori-utsugi extract and the application to skin anti-aging agents based on their effectiveness.
一方、当業者によって、植物抽出物に限らず、様々な原料の配合に基づいた様々な剤型の皮膚外用剤の一種であるスキンケア・メイク化粧料組成物が提案されている。(非特許文献4) On the other hand, those skilled in the art have proposed skin care and makeup cosmetic compositions which are a kind of external preparations for skin of various types based on the combination of various raw materials, not limited to plant extracts. (Non-patent document 4)
しかしながら、同様に、ノリウツギ抽出物の抗炎症機能、抗糖化機能、保湿機能の存在について記載または示唆されたものはない。 However, likewise, nothing has been described or suggested as to the presence of the anti-inflammatory function, anti-glycation function, moisturizing function of the Nori-utsugi extract.
また、これらの機能を有するノリウツギ抽出物を有効成分とした抗炎症剤、抗糖化剤、保湿剤並びにこれらを配合した皮膚老化防止剤及び皮膚外用剤についての応用可能性について記載または示唆されたものも存在しない。 In addition, those described or suggested about the applicability of anti-inflammatory agents, anti-glycation agents, moisturizers, and skin anti-aging agents and external preparations for skins comprising these extracts containing Nori-utsugi extract having these functions as an active ingredient There is also no.
抗炎症性、抗糖化性、保湿性といった多面的な効果を有する皮膚老化防止剤及びそれを含有する皮膚外用剤を提供する。 Provided are a skin anti-aging agent having multiple effects such as anti-inflammatory property, anti-glycation property and moisturizing property, and a skin external preparation containing the same.
発明者らは、ノリウツギの未知の有用性に着目し、その効果について探索と研究を進めていたところ、驚くべきことに、優れた抗炎症性、抗糖化性、保湿性、皮膚バリア効果を有することを見出し、発明を完成した。また、非特許文献4に例示されている皮膚外用剤として、さらには各種剤形に賦形するにあたっての、より最適な条件を見出すことに成功し、さらなる発明を完成した。 The inventors focused on the unknown usefulness of Noriutsugi and proceeded with the search and study on its effect, and surprisingly, it has excellent anti-inflammatory properties, anti-glycation properties, moisturizing properties, and skin barrier effects. Found out and completed the invention. In addition, as a skin external preparation exemplified in Non-patent Document 4, it succeeded in finding more optimal conditions for forming into various dosage forms, and completed a further invention.
本発明は、抗炎症性、抗糖化性、保湿性、といった多面的に優れた効果を有するノリウツギの抽出物からなる皮膚老化防止剤を提供することができるので、単独要因に対する効果が確認されているに過ぎない既存の抗老化剤よりも、皮膚老化の諸要因に対して幅広く対応することができ、あるいは、複数の皮膚老化防止剤を必ずしも必要としない皮膚外用剤を提供することができる。 Since the present invention can provide a skin anti-aging agent comprising an extract of Noriuchigi having multifaceted excellent effects such as anti-inflammatory property, anti-glycation property, moisturizing property, the effect on a single factor is confirmed It is possible to provide a skin external preparation that can respond to various factors of skin aging more broadly than existing anti-aging agents, or does not necessarily require a plurality of anti-aging agents.
ノリウツギ抽出物単体でも使用できるが、各種の様態の外用剤(医薬品・医薬部外品・化粧品など薬事上の分類を問わない)として調製し使用者の利便性を向上することができる。特に皮膚外用剤の調製にあたっては、例えば非特許文献4に紹介されている調剤例を用いることができる。 Although it is possible to use the extract alone, it can be prepared as various forms of external preparations (regardless of classification on medicines, quasi-drugs, cosmetics, etc.) to improve the convenience of the user. In particular, for preparation of a skin external preparation, for example, the preparation example introduced in Non-patent Document 4 can be used.
[ノリウツギ抽出物の調製]
植物原料から抽出物を調製する一般的方法を適宜採用することができるが、溶媒抽出法が望ましい。溶媒抽出については、水、エタノール等の極性溶媒を用いることが望ましく、水とその他の極性溶媒を同時に用いることがさらに望ましい。さらに、抽出物を活性炭処理、液液分配、カラムクロマトグラフィー、液体クロマトグラフィー、ゲル濾過、等によって、分離精製し、さらに活性の高い画分(成分)を抽出することもできる。
また、抽出部位は、全草を使用することもできるが、配合効率の観点から、特に、花・実を使用することが望ましい。
[Preparation of Noritsugi Extract]
General methods for preparing extracts from plant material can be employed as appropriate, but solvent extraction is preferred. For solvent extraction, it is desirable to use a polar solvent such as water and ethanol, and it is more desirable to use water and other polar solvents simultaneously. Furthermore, the extract can be separated and purified by activated carbon treatment, liquid-liquid distribution, column chromatography, liquid chromatography, gel filtration and the like to extract an active fraction (component).
Moreover, although the extraction site can also use whole grass, it is desirable to use especially flowers and fruits from the viewpoint of compounding efficiency.
[外用剤の調製]
外用剤、例えば化粧料として調製する場合、パウダー、パウダーファンデーション等の粉体、石けん、リップスティック等の固体、クリーム、乳液、クリームファンデーション等の乳化物、化粧水、美容液等の液体など、種々の形態に調製することが出来る。また、シャンプー、トリートメント、頭皮用皮膚外用剤であってもよい。
[Preparation of external preparation]
For external use, for example, when prepared as a cosmetic, powder, powder foundation such as powder foundation, soap, solid body such as lipstick, cream, emulsion, emulsion such as milky lotion, cream foundation, liquid such as lotion, cosmetic liquid etc. It can be prepared in the form of Moreover, it may be a shampoo, a treatment, and a skin external preparation for scalp.
この場合に配合し得る他の成分としては、通常、化粧品、医薬品等の外用剤の基剤成分あるいは添加剤成分または機能性を賦与する目的で用いられる成分、例えば、液状油分、固形油分、各種界面活性剤、金属セッケン、保湿剤、ゲル化剤、水溶性高分子、低級アルコール、多価アルコール、糖類、紫外線吸収剤、皮膜形成剤、樹脂、包接化合物、消臭剤、アミノ酸類、ビタミン類、薬剤、植物・動物・微生物由来の抽出物、有機酸、有機アミン、金属イオン封鎖剤、酸化防止剤、抗菌剤、防腐剤、pH調整剤、清涼剤、香料、エモリエント剤、色素、美白剤、抗しわ剤、抗老化剤、抗炎症剤、発毛剤、育毛促進剤、活性酸素除去剤、血行促進剤、収斂剤、角質溶解剤、タンパク質分解酵素などの成分、および外用薬の薬効成分としてのステロイド剤、非ステロイド剤を含む抗炎症剤、免疫抑制剤、鎮痛消炎剤、抗菌剤、抗真菌剤、抗ウイルス剤、抗腫瘍剤、抗潰瘍・褥瘡剤、創傷被覆剤、循環改善剤、止痒剤、局所麻酔剤、酔い止め剤、ニコチン剤、女性ホルモン剤等が挙げられる。調製にあたっては、本発明のノリウツギ抽出物の配合量及び目的とする外用剤の種類に応じた常法(例えば非特許文献4の調剤例)を用いることが出来る。 In this case, as other components that can be blended, components generally used for the purpose of imparting base or additive components of external preparations such as cosmetics and pharmaceuticals, or functionality, such as liquid oil, solid oil, various Surfactants, metal soaps, moisturizers, gelling agents, water-soluble polymers, lower alcohols, polyhydric alcohols, saccharides, UV absorbers, film-forming agents, resins, inclusion compounds, deodorants, amino acids, vitamins , Drugs, extracts from plants, animals and microorganisms, organic acids, organic amines, sequestering agents, antioxidants, antibacterial agents, preservatives, pH adjusters, fresheners, fragrances, emollients, dyes, whitening , Anti-wrinkle agent, anti-aging agent, anti-inflammatory agent, hair growth agent, hair growth promoting agent, active oxygen removing agent, blood circulation promoting agent, astringent agent, keratolytic agent, components such as proteolytic enzyme, and efficacy of external medicine As an ingredient Anti-inflammatory agents including non-steroidal agents, immunosuppressive agents, analgesic / anti-inflammatory agents, antibacterial agents, anti-fungal agents, anti-viral agents, anti-tumor agents, anti-ulcers, anti-ulcer agents, wound covering agents, circulation improving agents, stop There may be mentioned lozenges, local anesthetics, anti-sickness agents, nicotinic agents, female hormone agents and the like. In the preparation, it is possible to use a conventional method (for example, the preparation example of Non-Patent Document 4) according to the compounding amount of the Nori-tsutii extract of the present invention and the type of the intended external preparation.
以下の手順でノリウツギ抽出物を30%エタノール溶液として調製し、抗炎症作用、抗糖化作用について、精製水を比較例として、それぞれ後述の通り効果を検証した。
使用するノリウツギの抽出部位については、採取した全草から花及び実以外の部位を取り除いたものを使用した。
なお、特に記載のない場合、百分率は重量百分率を意味しており、以降も同様である。
According to the following procedure, Nori-utsugi extract was prepared as a 30% ethanol solution, and with respect to anti-inflammatory action and anti-glycation action, purified water was used as a comparative example to verify the effects as described later.
As for the extraction site of Nori-utsugi to be used, one obtained by removing a site other than flowers and fruits from the whole plant collected was used.
In addition, unless otherwise indicated, percentage means weight percentage, and so on.
<ノリウツギ抽出物(30%エタノール溶液)調製法>
1.乾燥したノリウツギ100gを粉砕し、95%エタノール500gを加えた。
2.40℃で120分撹拌抽出した。
3.さらに500g加水した後、5%水酸化ナトリウム水溶液を添加してpH13〜14に調整した。
4.70℃まで加熱した後、10%乳酸を添加してpH6.5に調整した。
5.室温まで徐放した後、30%エタノール溶液になるよう加水し、ノリウツギ抽出物(30%エタノール溶液)を得た。
<Preparation method of Noriutsugi extract (30% ethanol solution)>
1. One hundred grams of dried ginseng was ground and 500 g of 95% ethanol was added.
2. Extracted with stirring at 40 ° C. for 120 minutes.
3. After 500 g of water was further added, a 5% aqueous solution of sodium hydroxide was added to adjust to pH 13-14.
After heating to 4.70 ° C., 10% lactic acid was added to adjust to pH 6.5.
5. After slowing down to room temperature, the solution was hydrolyzed to a 30% ethanol solution to obtain a Japanese apricot extract (30% ethanol solution).
[抗炎症作用の検証]
ノリウツギ抽出物の炎症性サイトカイン産生抑制作用をinterleukin-8(IL-8)およびtumor necrosis factor- alpha(TNF-α)の遺伝子発現を指標に調べた。
試験は以下のように行った。
培養した正常ヒト表皮角化細胞(NHEK)を0.2%ノリウツギ抽出物(「ノリウツギ抽出物(30%エタノール溶液)」を加水希釈してノリウツギ抽出物として0.2%含有したもの。以下同じ。)で24時間処理した。
その後、さらに、2μg/mlリポ多糖(LPS; グラム陰性菌の細胞壁成分であり炎症を惹起する)および0.2%ノリウツギ抽出物で6時間処理した。
処理後の細胞からRNAを抽出し、EcoTM Real time PCR system(illumina)を用いてRT-PCR法でIL-8およびTNF-αの遺伝子発現を調べた。
[Verification of anti-inflammatory effect]
The inflammatory cytokine production inhibitory action of Nori-utsugi extract was investigated using gene expression of interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α) as an index.
The test was performed as follows.
0.2% of a cultured normal human epidermal keratinocytes (NHEK) containing 0.2% of a 0.2% extract as an extract by hydrolyzing a 0.2% extract from a Japanese rosewood extract (30% ethanol solution). Processed for 24 hours.
Thereafter, the cells were further treated with 2 μg / ml lipopolysaccharide (LPS; cell wall component of gram negative bacteria to cause inflammation) and 0.2% prickly pear extract for 6 hours.
RNA was extracted from the treated cells, and gene expression of IL-8 and TNF-α was examined by RT-PCR method using EcoTM Real time PCR system (illumina).
ノリウツギ抽出物のNF-κBの活性化抑制作用をNF-κBのサブユニットの一つであるp65の核内レベルを指標に調べた。
試験は以下のように行った。培養したNHEKを0.2%ノリウツギ抽出物で24時間処理した。その後、さらに、2μg/ml LPSおよび0.2%ノリウツギ抽出物で1時間処理した。
処理後の細胞から核タンパク質を抽出し、ウエスタンブロッティングでp65の発現レベルを調べた。
The NF-κB activation inhibitory action of the Japanese apricot extract was examined using the nuclear level of p65, which is one of the subunits of NF-κB, as an indicator.
The test was performed as follows. The cultured NHEK was treated for 24 hours with 0.2% water lily extract. After that, it was further treated with 2 μg / ml LPS and 0.2% Sesium extract for 1 hour.
Nuclear proteins were extracted from the treated cells, and the expression level of p65 was examined by Western blotting.
以上のことから、ノリウツギ抽出物は、炎症性サイトカインの発現遺伝子の生成抑制効果を有する優れた抗炎症剤であることがわかる。 From the above, it can be seen that Nori-utsugi extract is an excellent anti-inflammatory agent having an effect of suppressing the production of the expression gene of inflammatory cytokines.
[抗糖化作用の検証]
ノリウツギ抽出物の抗糖化作用を糖化誘導物質グリオキサール(glyoxal)により形成されるAGEsを指標に調べた。
試験は以下のように行った。
培養した正常ヒト真皮線維芽細胞(NB1RGB)をglyoxalおよび0.2%ノリウツギ抽出物で24時間処理した。
処理後の細胞からタンパク質を抽出し、Bio-Dot Microfiltration Apparatus(Bio-RAD)を用いてドットブロッティングでAGEsの形成レベルを調べた。
[Verification of antiglycation effect]
The anti-glycation activity of Nori-utsuji extract was examined using AGEs formed by the glycation inducer glyoxal as an indicator.
The test was performed as follows.
Cultured normal human dermal fibroblasts (NB1 RGB) were treated for 24 hours with glyoxal and 0.2% Sesium extract.
Protein was extracted from the treated cells, and the formation level of AGEs was examined by dot blotting using Bio-Dot Microfiltration Apparatus (Bio-RAD).
ノリウツギ抽出物の抗糖化作用をglyoxalにより形成されたAGEsの分解を指標に確認した。試験は以下のように行った。
培養したNHEKをglyoxalで24時間処理した。
処理後、glyoxalを除去し、0.2%ノリウツギ抽出物で24時間処理した。
処理後の細胞からタンパク質を抽出し、Bio-Dot Microfiltration Apparatus(Bio-RAD)を用いてドットブロッティングでAGEsの分解を調べた。
The anti-glycation activity of the Nori-tsugi extract was confirmed using the degradation of AGEs formed by glyoxal as an indicator. The test was performed as follows.
The cultured NHEK was treated with glyoxal for 24 hours.
After treatment, the glyoxal was removed and treated with 0.2% water lily extract for 24 hours.
Proteins were extracted from the treated cells, and degradation of AGEs was examined by dot blotting using Bio-Dot Microfiltration Apparatus (Bio-RAD).
以上のことから、ノリウツギ抽出物は、AGEsの抑制効果と分解効果の両方を併せ持つ、優れた抗糖化剤であることがわかる。 From the above, it can be seen that the Nori-utsugi extract is an excellent anti-glycation agent having both the AGEs suppressing effect and the degrading effect.
ノリウツギ抽出物を配合した皮膚外用剤の調剤例として以下の化粧料を調製した。 The following cosmetics were prepared as a preparation example of the skin external preparation which mix | blended the rosewood extract.
[化粧水]
実施例1のノリウツギ抽出物(30%エタノール溶液)を使用して以下の構成成分を常法で調製した。(表中のノリウツギ抽出物は、このノリウツギ抽出物(30%エタノール溶液)をいう。以下同じ。)
また、比較例として、ノリウツギ抽出物(30%エタノール溶液)を精製水で置換したものを調製した。
The following components were prepared in a conventional manner using the extract of Example 1 (30% ethanol solution). (The Nori-utsugi extract in the table refers to this Nori-tsutii extract (30% ethanol solution). The same shall apply hereinafter.)
Further, as a comparative example, a product in which Noriuchigi extract (30% ethanol solution) was replaced with purified water was prepared.
[ローション]
実施例1のノリウツギ抽出物(30%エタノール溶液)を使用して以下の構成成分を常法で調製した。
また、比較例として、ノリウツギ抽出物(30%エタノール溶液)分を精製水で置換したものを調製した。
The following components were prepared in a conventional manner using the extract of Example 1 (30% ethanol solution).
In addition, as a comparative example, a product in which a part of Noriuchigi extract (30% ethanol solution) was replaced with purified water was prepared.
[クリーム剤]
実施例1のノリウツギ抽出物(30%エタノール溶液)を使用して以下の構成成分を常法で調製した。
また、比較例として、ノリウツギ抽出物(30%エタノール溶液)分を精製水で置換したものを調製した。
The following components were prepared in a conventional manner using the extract of Example 1 (30% ethanol solution).
In addition, as a comparative example, a product in which a part of Noriuchigi extract (30% ethanol solution) was replaced with purified water was prepared.
[パック剤]
実施例1のノリウツギ抽出物(30%エタノール溶液)を使用して以下の構成成分を常法で調製した。
また、比較例として、ノリウツギ抽出物(30%エタノール溶液)分を精製水で置換したものを調製した。
The following components were prepared in a conventional manner using the extract of Example 1 (30% ethanol solution).
In addition, as a comparative example, a product in which a part of Noriuchigi extract (30% ethanol solution) was replaced with purified water was prepared.
以下に、実施例2から5及び対応する比較例を対象にモニター官能評価での効果検証結果を示す。
なお、検証にあたっては、女性従業員から選抜した健常な皮膚を有するモニター3名に、実施例2の化粧水を複数回使用させ、化粧料、特にスキンケア化粧料において求められ、また、皮膚老化の指標とされている「うるおい」「なめらかさ」「やわらかさ」「つや」「透明感」「ハリ」「総合評価」について評価した。このとき、「1.感じない、2.あまり感じない、3.どちらともいえない、4.やや感じる、5.感じる」の5段階で判定したものの平均値を採用し検証した。
Below, the effect verification result in monitor sensory evaluation is shown for Examples 2 to 5 and a corresponding comparative example.
In addition, in verification, three monitors having healthy skin selected from a female employee are caused to use the lotion of Example 2 a plurality of times, and are required for cosmetics, particularly skin care cosmetics, and also for skin aging. We evaluated the "water,""smoothness,""softness,""gloss,""transparency,""harry," and "overall evaluation," which are considered to be indicators. At this time, the average value of what was judged in five steps of "1. not feel, 2. not felt much, 3. neither can say 4. somewhat feel, 5. feel" was adopted and verified.
本発明の化粧品組成物は、外用化粧品としてメーキャップ化粧品やスキンケア化粧品(機能性化粧品)のベース基剤としてだけでなく、水分蒸発抑制機能による保湿効果をもつ機能性化粧品としても利用できる。また、薬事上の各種基準・要件を備えることによって、医薬部外品及び医薬品にも利用することができる。 The cosmetic composition of the present invention can be used not only as a base for makeup cosmetics and skin care cosmetics (functional cosmetics) as external cosmetics but also as functional cosmetics having a moisturizing effect by a water evaporation suppressing function. In addition, by providing various standards and requirements on pharmaceutical matters, it can be used for quasi drugs and medicines.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017080347A JP2018177702A (en) | 2017-04-14 | 2017-04-14 | Skin aging inhibitor containing hydrangea paniculata siebold extract as active ingredient and skin external preparation containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017080347A JP2018177702A (en) | 2017-04-14 | 2017-04-14 | Skin aging inhibitor containing hydrangea paniculata siebold extract as active ingredient and skin external preparation containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2018177702A true JP2018177702A (en) | 2018-11-15 |
Family
ID=64282199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080347A Pending JP2018177702A (en) | 2017-04-14 | 2017-04-14 | Skin aging inhibitor containing hydrangea paniculata siebold extract as active ingredient and skin external preparation containing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2018177702A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022034833A1 (en) * | 2020-08-11 | 2022-02-17 |
-
2017
- 2017-04-14 JP JP2017080347A patent/JP2018177702A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022034833A1 (en) * | 2020-08-11 | 2022-02-17 | ||
| WO2022034833A1 (en) * | 2020-08-11 | 2022-02-17 | 株式会社 資生堂 | Il-8 inhibitor, anti-aging agent for skin, and method for controlling skin aging using same |
| CN116322731A (en) * | 2020-08-11 | 2023-06-23 | 株式会社资生堂 | IL-8 inhibitors, skin anti-aging agents, and methods of using them to inhibit skin aging |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7076534B2 (en) | Cosmetic composition containing dendrobium candidum flower extract | |
| EP2356977B1 (en) | Preparations with wood extracts of Gleditsia | |
| TW201206494A (en) | Use of Tiliacora triandra in cosmetics and compositions thereof | |
| JP6054700B2 (en) | Desugaring agent and external preparation for skin | |
| JP6196346B2 (en) | Use of lignan compounds to improve wrinkles | |
| JP7708495B2 (en) | Anti-aging agents, antioxidants, anti-inflammatory agents, skin whitening agents, and cosmetics | |
| JP2011088845A (en) | Involucrin expression inhibitor | |
| KR20140012456A (en) | Composition for improving skin conditions comprising akebia saponin d | |
| JP2020502172A (en) | Cosmetic composition containing Chinese herbal extract as active ingredient | |
| KR102530813B1 (en) | Composition for improving skin transparency and dullness | |
| KR20100001167A (en) | Cosmetic composition comprising quercitrin and/or myricitrin as active ingredients | |
| KR101757674B1 (en) | Cosmetic Composition Comprising Extracts of Bidens bipinnata for Enhancing Skin Tightening and Improving Skin Wrinkle | |
| KR101793104B1 (en) | Cosmetic composition for whitening skin comprising mixed extract of Cudrania tricuspidata leaf and Morus alba leaf as effective component | |
| KR101587077B1 (en) | Composition containing fermentated opuntia humifusa showing biological activity of skin | |
| KR102513248B1 (en) | Composition comprising undaria pinnatifida sporophyll extract treated with pulsed electric field | |
| JP2018177702A (en) | Skin aging inhibitor containing hydrangea paniculata siebold extract as active ingredient and skin external preparation containing the same | |
| KR101974502B1 (en) | Cosmetic composition for anti-allergy and for improving atopic dermatitis comprising extract of anemone reflexa stephan as active ingredient | |
| KR102221627B1 (en) | Composition comprising Rhus Semialata extract as active ingredient | |
| JP2002284648A (en) | Hair restorer composition | |
| KR101686521B1 (en) | Composition for beauty of skin | |
| KR20140114709A (en) | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract | |
| JP5896618B2 (en) | Melanin production inhibitor | |
| KR100331675B1 (en) | External skin preparation | |
| JP6843537B2 (en) | Anti-skin aging agent and topical cosmetics containing it | |
| JP2778855B2 (en) | Cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170501 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20170501 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20170501 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170623 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200309 |